Skip to main content

Advertisement

SpringerLink
Log in

Organ Damage and Quality of Life in Antiphospholipid Syndrome

  • Antiphospholipid Syndrome (S Zuily, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Antiphospholipid syndrome (APS) affects young patients in the most productive years of their life, and the consequences of organic or tissue damage involve a decrease in health-related quality of life (HRQoL). While acute disease manifestations of APS are well known, information on the long-term prognosis and damage in affected patients is still very limited. Systemic lupus erythematosus (SLE) patients would be expected to experience long-term complications and even die as a consequence of APS. Organ damage in APS has been evaluated using different methods and definitions, including the SLICC/ACR Damage Index (SDI), which tend to underestimate aPL-related damage. A new damage index in APS has been proposed (DIAPS), and it seems to be more accurate than SDI. Given the implications for morbidity and mortality, it is imperative to assess accurately aPL-related damage and HRQoL in patients with APS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000;9:322–7.

    Article  CAS  PubMed  Google Scholar 

  2. Fischer-Betz R, Schneider M. Connective tissue diseases: evaluation of clinical response. Rheumatology (Oxford). 2008;47(2):234–5.

    Google Scholar 

  3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  CAS  PubMed  Google Scholar 

  4. Merashli M, Hassan M, Noureldine A, et al. Antiphospholipid syndrome: an update. Eur J Clin Invest. 2015;45:653–62.

    Article  PubMed  Google Scholar 

  5. Amigo MC. What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus. 2014;23:1259–61.

    Article  PubMed  Google Scholar 

  6. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303–8.

    Article  CAS  PubMed  Google Scholar 

  7. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.

    CAS  PubMed  Google Scholar 

  8. Jallow T, D’Cruz D, Lempp H. Antiphospholipid syndrome. BMJ. 2015;350:h1426.

    Article  PubMed  Google Scholar 

  9. Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, Croal B, Ramsay CR, Brazzelli M. Is self.monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 2015 (6): e007758.

  10. Gladman DD, Urowitz MB, Goldsmith CH, Bacon P, Fortin P, Ginzler E, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.

    Article  CAS  PubMed  Google Scholar 

  11. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27:373–6.

    CAS  PubMed  Google Scholar 

  12. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93–6.

    Article  CAS  PubMed  Google Scholar 

  13. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002;29:1398–400.

    PubMed  Google Scholar 

  14. Cardoso CR, Signorelli FV, Papi JA, Salles GF. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus. 2008;17:1042–8.

    Article  CAS  PubMed  Google Scholar 

  15. Goncalves MJ, Sousa S, Inès LS, et al. Characterization of damage in Portuguese lupus patients: analysis of a National Lupus Registry. Lupus. 2015;24:256–62.

    Article  CAS  PubMed  Google Scholar 

  16. Ruiz Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus. 2004;13:900–5.

    Article  CAS  PubMed  Google Scholar 

  17. Ruiz Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164:77–82.

    Article  PubMed  Google Scholar 

  18. Cervera R, Serrano R, Pons-Estel GJ, on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011–8. An important paper describing a series of 1000 European APS patients with a long term follow-up.

    Article  CAS  PubMed  Google Scholar 

  19. Grika EP, Ziakas PD, Zintzaras E, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012;39:516–23. This study describes morbidity, organ damage, and cause of death in Greek patients with APS after a long-term follow-up.

    Article  PubMed  Google Scholar 

  20. Barbhaiya M, Erkan D, Rodriguez-Alamraz E, Ramón G, Vega J, Lockshin MD. Utility of the Systemic Lupus International Collaborating Clinics (SLICC) American College of Rheumatology (ACR) Damage Indexfor antiphospholipid antibody (aPL) positive patients. Arthritis Rheum. 2011;63:Suppl:S3.

    Google Scholar 

  21. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24:927–34. This paper is of importance as it describes for the first time, the development of a specific damage index for thrombotic APS.

    Article  PubMed  Google Scholar 

  22. Holzer LA, Sevelda F, Fraberger G, Bluder O, Kickinger W, Holzer G. Body image and self-esteem in lower-limb amputees. PLoS One. 2014;9:e92943.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary sntiphospholipid syndrome: functional outcome after 10 years. J Rheumatol. 2000;27:2817–21.

    CAS  PubMed  Google Scholar 

  24. Dall’Ara F, Reggia R, Taraborelli M, Andreoli L, Taglietti M, Frassi M, et al. Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus. 2014;23:1255–8.

    Article  PubMed  Google Scholar 

  25. Tektonidou MG, Ioannidis JP, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000;93:523–30.

    Article  CAS  PubMed  Google Scholar 

  26. Ugolini Lopes M, Aguila L, Tonon R et al. SLICC and DIAPS. Potential indices for damage assessment in primary antiphospholipid syndrome (PAPS). Presented at APLA & LACA 2013, 14th International Congress on Antiphospholipid Antibodies. 18–21 September 2013. Rio de Janeiro, Brazil.

  27. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.

    Article  PubMed  Google Scholar 

  28. Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2003;5:395–400.

    Article  PubMed  Google Scholar 

  29. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998;77:195–207.

    Article  CAS  Google Scholar 

  30. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis. 2007;66:740–6.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cervera R, Bucciarelli S, Plasin MA, Gómez-Puerta JA, Plaza J, Pons-Estel GJ, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009;32:240–5.

    Article  CAS  PubMed  Google Scholar 

  33. Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.

    Article  CAS  PubMed  Google Scholar 

  34. Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–76.

    Article  PubMed  Google Scholar 

  36. Asherson RA, Cervera R, Klumb E, Stojanovic L, Sarzi-Puttini P, Yinh J, et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum. 2008;38:124–31.

    Article  PubMed  Google Scholar 

  37. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Semin Arthritis Rheum. 2013;42:417–23.

    Article  PubMed  Google Scholar 

  39. WHOQOL User manual. Geneva.World Health Organization 1998:61–71.

  40. Boers M, Brooks P, Strand V, et al. The OMERACT filter for outcomes measures in rheumatology. J Rheumatol. 1998;25:198–9.

    CAS  PubMed  Google Scholar 

  41. Geryk LL, Carpenter DM, Blalock SJ, De Vellis RF, Jorda JM. The impact of co-morbidity on HRQL in rheumatoid arthritis and osteoarthritis patients. Clin Exp Rheumatol. 2015;33:366–74.

    PubMed  Google Scholar 

  42. Strand V, Singh JA. Improved Health related Quality of Life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2007 Suppl 9:S237-251.

  43. Ware JE, Sherburne CD. The MOS 36-item short form health survey (SF36) I: concept framework and item election. Med Care. 1992;30:473–83.

    Article  PubMed  Google Scholar 

  44. Euro-Qol A new facility for the measurement of health-related quality of life. Te EuroQol group. Health policy 1990;16:199–208.

  45. Picavet HSJ, Hoeymans. Health related quality of life in multiple musculoskeletal diseases: SF36 and EQ-ED in the DMC3 study. Annals Rheum Dis. 2004;63:723–729.

  46. Use of sort form SF36 for health status in British patients with RA. Reliability, validity and responsiveness of the sort form 36-item health survey. Br J Rheumatol 1998;37:425–436.

  47. Ware JE. SF-36 health survey update. Lincoln: Quality-Metric Incorporated; 2007.

    Google Scholar 

  48. Wang S-l, Wu B, Zhu L-a, Leng L, Bucala R, et al. Construct and criterion validity of the euro Qol-5D in patients with systemic lupus erythematosus. PLoS One. 2014;9:e98883. doi:10.1371/journal.pone.0098883.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Wang C, Mayo N, Fortin P. The relationship between related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001;28:3.

    Google Scholar 

  50. García-Carrasco M, Mendoza-Pinto C, Cardiel MH, Méndez-Martínez S, García-Villaseñor A, Jiménez-Hernández C, et al. Health related quality of life in mexican women with systemic lupus erythematosus: a descriptive study using SF36 and LupusQol. Lupus. 2012;21:1219–24. This descriptive study evaluated HRQoL in a large group of Mexican SLE patients.

    Article  PubMed  Google Scholar 

  51. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus an update. Ann Acad Med Singap. 2007;36:115–22.

    PubMed  Google Scholar 

  52. Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015;13:16. Important review demonstrating differences between thrombosis associated with SLE and, with APS.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Balitsy AK, Peeva V, Su J, et al. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2011;38:1017–9.

    Article  Google Scholar 

  54. Mevorach-Zussman N, Bolotin A, Shalev BA, Bilenko N, Mazor M, Bashiri A. Anxiety and deterioration of quality of life factors associated with recurrent miscarriage in an observational study. J Perinat Med. 2012;40:495–501. An important paper describing QoL in cases with recurrent miscarriage, includingAPS patients.

    PubMed  Google Scholar 

  55. Mathew S, Cesario S, Symes L. Explaining “unexplainded” perinatal loss. Experiences of women with antiphospholipid syndrome. J Perinat Neonat Nurs. 2008;22:293–301.

    Article  Google Scholar 

  56. Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, Khamashta. Efficacy and safety of long-term low molecular weight heparin in patiens with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–1654.

  57. Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B. Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health. 2015;129:954–62.

    Article  CAS  PubMed  Google Scholar 

  58. Georgopoulou S, Efraimidou S, MacLennan SJ, Ibrahim F, Cox T. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using SF36. Lupus. 2015;24:174–9. First survey that evaluates population with APS exploring patients qualitative view of their disease.

    Article  CAS  PubMed  Google Scholar 

  59. Zuily S. Rat AC, Regnault V, Kaminsky P, Mismetti P, Ninet J, Baillet N, Magy-Bertrand N. Pasquali J-L, Lambert M, Pasquier E, Lorcerie B, Lecompte L, Guillemin F, Whal D. and TAC(1)C investigators. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus. 2015;24:1161–1168. Highly recommended survey that compares the quality of life in patients with APS, SLE, and the general population. Cardiovascular comorbidities and thrombosis are considered.

Download references

Acknowledgments

We gratefully acknowledge Professor Juan J. Canoso for reviewing this manuscript.

Author information

Authors and Affiliations

  1. Hospital Córdoba, Cátedra de Medicina I UHMI n 3, Universidad Nacional de Córdoba, Libertad No. 2051, Córdoba, 5000, Argentina

    P. Alba

  2. Grupo de Inmunología Celular e Inmunogenética (GICIG), Universidad de Antioquia, Calle 67 No. 53-108, Medellín, Colombia

    J. A. Gómez-Puerta

  3. Unidad de Investigación en Epidemiología Clínica, Hospital General Regional No. 1, IMSS, Universidad Nacional Autónoma de México, Gabriel Mancera # 222, Mexico City, 03100, Mexico

    M. V. Goycochea-Robles

  4. Centro Médico ABC, Universidad Nacional Autónoma de México, Sur 136 No. 116, Mexico City, 01120, Mexico

    M. C. Amigo

Authors
  1. P. Alba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. A. Gómez-Puerta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. V. Goycochea-Robles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. C. Amigo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. C. Amigo.

Ethics declarations

Conflict of Interest

Paula Alba, Jose A. Gómez-Puerta, María Victoria Goycochea-Robles, and Mary-Carmen Amigo declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Antiphospholipid Syndrome

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alba, P., Gómez-Puerta, J.A., Goycochea-Robles, M.V. et al. Organ Damage and Quality of Life in Antiphospholipid Syndrome. Curr Rheumatol Rep 18, 7 (2016). https://doi.org/10.1007/s11926-015-0556-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0556-6

Keywords

Search

Navigation